Literature DB >> 22871998

Ammonia-lowering strategies for the treatment of hepatic encephalopathy.

C F Rose1.   

Abstract

Hyperammonemia leads to neurotoxic levels of brain ammonia and is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia-lowering treatments primarily involve two strategies: inhibiting ammonia production and/or increasing ammonia removal. Targeting the gut has been the primary focus for many years, with the goal of inhibiting the generation of ammonia. However, in the context of liver failure, extrahepatic organs containing ammonia metabolic pathways have become new potential ammonia-lowering targets. Skeletal muscle has the capacity to remove ammonia by producing glutamine through the enzyme glutamine synthetase (amidation of glutamate) and, given its large mass, has the potential to be an important ammonia-removing organ. On the other hand, glutamine can be deaminated to glutamate by phosphate-activated glutaminase, thus releasing ammonia (ammonia rebound). Therefore, new treatment strategies are being focused on stimulating the removal of both ammonia and glutamine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871998     DOI: 10.1038/clpt.2012.112

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

1.  Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

Authors:  Avinash Kumar; Gangarao Davuluri; Rafaella Nascimento E Silva; Marielle P K J Engelen; Gabrie A M Ten Have; Richard Prayson; Nicolaas E P Deutz; Srinivasan Dasarathy
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

Review 2.  Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease.

Authors:  Rafael Ochoa-Sanchez; Christopher F Rose
Journal:  J Clin Exp Hepatol       Date:  2018-08-18

Review 3.  Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.

Authors:  Rune Gangsoy Kristiansen
Journal:  Metab Brain Dis       Date:  2016-09-21       Impact factor: 3.584

4.  Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Authors:  Harry D Zacharias; Antony P Zacharias; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-17

Review 5.  When can nutritional therapy impact liver disease?

Authors:  Matthew C Bozeman; Matthew V Benns; Stephen A McClave; Keith R Miller; Christopher M Jones
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 6.  Nutrition and Muscle in Cirrhosis.

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2017-11-08

Review 7.  Ammonia, like K(+), stimulates the Na(+), K(+), 2 Cl(-) cotransporter NKCC1 and the Na(+),K(+)-ATPase and interacts with endogenous ouabain in astrocytes.

Authors:  Leif Hertz; Liang Peng; Dan Song
Journal:  Neurochem Res       Date:  2014-06-15       Impact factor: 3.996

8.  Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia.

Authors:  M A Torres-Vega; R Y Vargas-Jerónimo; A G Montiel-Martínez; R M Muñoz-Fuentes; A Zamorano-Carrillo; A R Pastor; L A Palomares
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

9.  Sodium benzoate for treatment of hepatic encephalopathy.

Authors:  Michael L Misel; Robert G Gish; Heather Patton; Michel Mendler
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04

Review 10.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.